This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.
The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma
October 5th 2022During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.
Approaches to Manage Frontline Therapy for Multiple Myeloma
March 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.
Discussing the Future Role of Stem Cell Transplant in Multiple Myeloma
April 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants their thoughts on the future of transplantation in multiple myeloma. This is the second of 2 articles based on this event.
Looking At Therapy Past Transplantation in Newly Diagnosed Multiple Myeloma
July 6th 2023In the second article of a 2-part series, Alfred Garfall, MD, discussed how to best treat patients with multiple myeloma after they undergo transplant and whether continuing quadruplet therapy can provide a benefit before maintenance therapy.
Trials Shed Light on Transplant and Maintenance in NDMM
December 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.
Quadruplet Trials Form New Standard in Transplant-Eligible Multiple Myeloma
January 9th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.